Secondary hyperparathyroidism clusters in the sickest adult congenital heart disease patients
Secondary hyperparathyroidism is not a niche laboratory abnormality in adult congenital heart disease. In the CHD-HYPER study, secondary hyperparathyroidism appeared in 14.9% of 754 adults with congenital heart disease, with the burden rising sharply in the most complex physiologies and in patients with substantial right heart involvement.
The pattern matters because this population already carries layered risks from chronic cyanosis, venous congestion, renal dysfunction, abnormal hepatic hemodynamics, and long-standing exposure to diuretics. Parathyroid hormone excess often develops as a response to disturbed mineral metabolism, low vitamin D status, and impaired kidney handling of calcium and phosphate. In adult congenital heart disease, those drivers may converge rather than occur in isolation.
Highest prevalence in Eisenmenger syndrome, Fontan circulation, and other complex lesions
Prevalence varied dramatically across diagnostic groups. The highest rates of secondary hyperparathyroidism appeared in Eisenmenger syndrome/PAH-CHD at 39.1%, followed by Ebstein’s anomaly at 29.2%, Fontan palliation at 25%, and pulmonary atresia at 25%.
Patients with univentricular physiology showed a substantially greater burden than those with biventricular physiology: 29.6% versus 13.3%, with a reported P value below 0.001. The signal tracks with physiology more than diagnosis alone. Fontan circulation and other complex substrates can produce chronically elevated venous pressures, hepatic congestion, reduced cardiac output reserve, and renal hypoperfusion, all of which can disturb endocrine-mineral balance and accelerate the biology that drives parathyroid overactivity.
The prevalence gradient also suggests that sHPT may function as a marker of cumulative systemic stress rather than a stand-alone laboratory finding. In congenital heart disease, the endocrine system often registers what the hemodynamics have been doing for years.
Kidney function, vitamin D status, and diuretic exposure shaped the risk profile
Multivariable analysis identified several factors independently associated with sHPT across the full cohort: glomerular filtration rate, serum 25-hydroxyvitamin D₃, loop diuretic use, oxygen saturation, and liver stiffness. Each association points to a different piece of the same pathophysiological puzzle.
Reduced kidney function is a classic trigger for secondary hyperparathyroidism because impaired phosphate excretion and disordered vitamin D activation push calcium-parathyroid physiology toward compensation. Lower 25-hydroxyvitamin D₃ fits the same framework. Loop diuretics likely reflect both treatment intensity and disease severity, while lower oxygen saturation suggests a chronic hypoxemic burden that may intersect with bone-mineral regulation and organ dysfunction. Liver stiffness adds another layer, particularly in patients with venous congestion or congestive hepatopathy, where chronic right-sided pressure loading can spill into hepatic and metabolic consequences.
In practical terms, the model does not point to a single culprit. It describes a multi-organ phenotype in which renal impairment, nutritional or metabolic vitamin D deficiency, chronic cyanosis, and congestion travel together.
Right ventricular mechanics may matter more than left-sided strain in biventricular disease
Among patients with biventricular physiology, right ventricular free wall longitudinal strain showed a significant association with sHPT, whereas left ventricular global longitudinal strain did not. That separation is clinically interesting because adult congenital heart disease often becomes a disease of the right ventricle even when the left ventricle is structurally preserved.
The finding suggests that right-sided dysfunction may be more closely linked to the biochemical milieu associated with secondary hyperparathyroidism than left-sided systolic impairment. Right ventricular strain is a sensitive marker of early myocardial dysfunction, and in congenital heart disease it can reflect chronic pressure overload, volume loading, or both. A failing right ventricle can worsen systemic venous congestion, reduce renal perfusion, and amplify hepatic and renal derangements that destabilize calcium-phosphate homeostasis.
One sentence captures the bedside implication: right heart disease and parathyroid activation may be moving in the same direction.
Why this endocrine signal matters in congenital heart disease clinics
Adult congenital heart disease care increasingly depends on recognizing noncardiac manifestations of chronic cardiovascular physiology. Secondary hyperparathyroidism belongs in that conversation because it may indicate that the patient’s disease burden extends beyond the echo report and the electrocardiogram.
The study does not establish causation, and it does not show whether treating sHPT changes outcomes in this population. Even so, the prevalence is high enough to argue for attention when complex ACHD patients present with renal dysfunction, low oxygen saturation, liver disease, or long-term diuretic exposure. Those are the same patients in whom bone health, fracture risk, muscle function, and cardiovascular reserve can already be fragile.
The broader clinical issue is that parathyroid hormone excess may not be an isolated laboratory epiphenomenon. In the setting of congenital heart disease, it may be a biochemical readout of multisystem exhaustion. Identifying it could help clinicians understand which patients have crossed from stable compensated physiology into a more advanced systemic state.
What the CHD-HYPER study adds to everyday decision-making
This cross-sectional, single-centre analysis provides a clear message: sHPT is common across adult congenital heart disease, but it concentrates in patients with complex lesions and in those with predominant right heart involvement. The association with glomerular filtration rate, vitamin D status, loop diuretics, oxygen saturation, and liver stiffness offers a physiologic map for where clinicians should look first.
For follow-up clinics, the practical question is not whether every patient needs an expansive endocrine workup. The more immediate issue is recognizing which ACHD phenotypes warrant a lower threshold for checking calcium-phosphate metabolism, vitamin D levels, kidney function, and related markers when symptoms, congestion, or organ dysfunction accumulate.
The study also leaves open a critical next step: whether sHPT is simply a marker of advanced disease or part of the pathway by which complex congenital heart disease worsens long-term outcomes. That distinction cannot be answered by cross-sectional data alone, and the article does not provide longitudinal event rates, treatment response data, or outcome modification after correction of mineral abnormalities. Those unanswered points define the next research gap in this population.